SuperworthSenti Biosciences EPS SNTI
Diluted earnings per share by quarter and over the last twelve months, from 2021.
- Last 12 months, to Jun 30, 2026
- −$1.77
- Latest quarter, Q2 FY26
- −$0.41
- Fiscal year 2025
- −$3.19
Senti Biosciences' earnings per share was −$1.77 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$0.41.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$3.19 | n/a |
| FY2024 | −$12.08 | n/a |
| FY2023 | −$15.97 | n/a |
| FY2022 | −$53.80 | n/a |
| FY2021 | n/a | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$0.41 | n/a | −$1.77 | |
| Q1 FY26 | −$0.14 | n/a | −$1.92 | |
| Q4 FY25 | −$0.53 | n/a | −$3.19 | |
| Q3 FY25 | −$0.69 | n/a | −$3.33 | |
| Q2 FY25 | −$0.56 | n/a | −$8.95 | |
| Q1 FY25 | −$1.41 | n/a | −$10.84 | |
| Q4 FY24 | −$0.67 | n/a | −$12.08 | |
| Q3 FY24 | −$6.31 | n/a | −$15.60 | |
| Q2 FY24 | −$2.45 | n/a | −$12.65 | |
| Q1 FY24 | −$2.65 | n/a | −$14.42 | |
| Q4 FY23 | −$4.19 | n/a | −$15.97 | |
| Q3 FY23 | −$3.36 | n/a | −$15.98 |
Against its peers
Companies in Healthcare nearest Senti Biosciences' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| SNTISenti Biosciences | −$1.77 | |
| NEPHNephros | $0.16 | +33% a year |
| ATNMActinium Pharmaceuticals | $0.36 | |
| APTAlpha Pro Tech | $0.41 | +24% a year |
| Peer median | $0.36 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Senti Biosciences
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.